Shots:
- FDA has granted IND clearance to initiate D3S-003 a P-I, and a P-II combination study of D3S-001 (elisrasib), a next-gen KRAS G12C inhibitor, with D3S-002, an oral ERK1/2 inhibitor
- The P-II trial will evaluate the D3S-001 + D3S-002 combination in KRAS G12C–mutant NSCLC patients who have progressed on prior KRAS G12C therapies to assess safety, PK, and preliminary efficacy, aiming to overcome resistance and achieve more durable clinical benefit
- D3S-003 is an oral, allele-specific KRAS G12D inhibitor targeting both GDP- and GTP-bound states, showing better preclinical potency and safety, and will now advance into a P-I trial in KRAS G12D-mutant advanced solid tumors following FDA IND clearance
Ref: PR Newswire | Image: D3 Bio | Press Release
Related News: Ascletis Pharma Receives the US FDA IND Clearance to Initiate P-II Trial of ASC30 for Type 2 Diabetes
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
